Results 11 to 20 of about 142,623 (303)
British Journal of Pharmacology, 2006 British Journal of Pharmacology (2006) 147, S241–S251.
Gustav, Born, Carlo, Patrono
openaire +2 more sources
Frontiers in Surgery, 2023 IntroductionAround 20% of population in western countries is under anticoagulant treatment. However, there is paucity of evidence about the treatment of HD in patients under anticoagulant/antiplatelet therapy, although both suspension and continuation in
Francesco Pata +6 more
doaj +1 more source
Can Isoquinoline Alkaloids Affect Platelet Aggregation in Whole Human Blood?
Toxins, 2022 Isoquinoline alkaloids have multiple biological activities, which might be associated with positive pharmacological effects as well as negative adverse reactions.
Mst Shamima Parvin +8 more
doaj +1 more source
Preparation and Evaluation of 6-Gingerol Derivatives as Novel Antioxidants and Antiplatelet Agents
Antioxidants, 2023 Ginger (Zingiber officinale) is widely used as a spice and a traditional medicine. Many bioactivities have been reported for its extracts and the isolated compounds, including cardiovascular protective effects.
Sara H. H. Ahmed +9 more
doaj +1 more source
Biomedicines, 2021 The successful treatment of peripheral arterial disease (PAD) depends on adequate adherence to medications including antiplatelet agents. The aims of this study were (a) to identify the proportion of nonpersistent patients who reinitiated antiplatelet ...
Martin Wawruch +8 more
doaj +1 more source
Gut and Liver, 2018 Background/AimsCurrent guidelines recommend withholding antiplatelets for 5–7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding.Methods : Gastric ESD cases with ...
Sooyeon Oh +10 more
doaj +1 more source
Antiplatelets in Stroke Prevention [PDF]
Current Vascular Pharmacology, 2014 Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death ...
Antonio, Pinto +4 more
openaire +3 more sources
Journal of The Arab Society for Medical Research, 2023 Platelets play a major role in normal hemostatic and thrombotic processes. Aggregation of platelets presents the key pathophysiological step in the development of cardiovascular diseases; hence, antiplatelet agents remain crucial in the treatment of cardiovascular diseases. They may target the three principal phases leading to
Asma Haffouz +2 more
openaire +2 more sources
NOVEL APPROACH TO ANTITHROMBOTIC TREATMENT OF ACUTE CORONARY PATIENTS WITH RIVAROXABAN
Российский кардиологический журнал, 2015 Antithrombotic treatment of acute coronary syndrome leads to much better outcomes of the disease. The article focuses on the arguments and evidence for the addition to antiplatelet drugs the rivaroxaban 2,5 mg two times per day for secondary prevention ...
I. N. Bokarev, A. V. Golub
doaj +1 more source
Antiplatelets and Anticoagulants [PDF]
Clinical Cardiology, 2010 AbstractThose of us who see patients with cardiovascular disorders frequently use antiplatelet and anticoagulant agents; the common agents are aspirin, clopidogrel, and warfarin. This editorial is a personal viewpoint about commonly used drugs, not so commonly used drugs, and drugs that are yet to be used clinically. Copyright © 2010 Wiley Periodicals,
openaire +2 more sources